Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Payments to Acquire Debt Securities, Available-for-Sale

Payments to Acquire Debt Securities, Available-for-Sale at other companies

First BanCorp logo
First BanCorpFBP
$767.69M+6,160%
Simmons First National logo
Simmons First NationalSFNC
$13.34M+71.1%
SkyWest logo
SkyWestSKYW
$169.84M-51.4%
PureCycle Technologies, Inc. logo
PureCycle Technologies, Inc.PCT
$31.67M—
Popular logo
PopularBPOP
$10.39B+10.2%
Columbia Financial, Inc. logo
Columbia Financial, Inc.CLBK
$138.22M+113%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale?
Supernus Pharmaceuticals (SUPN) reported payments to acquire debt securities, available-for-sale of $78.44M in Q1 2026.
How has Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale changed year-over-year?
Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale decreased by 33.8% year-over-year, from $118.56M to $78.44M.
What is the long-term trend for Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's payments to acquire debt securities, available-for-sale has grown at a 11.2% compound annual growth rate (CAGR), from $311.57M to $475.94M.